Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation

<p>Abstract</p> <p>Background</p> <p>Human growth factor receptor bound protein 7 (Grb7) is an adapter protein that mediates the coupling of tyrosine kinases with their downstream signaling pathways. Grb7 is frequently overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell proliferation and migration. It is thus a prime target for the development of novel anti-cancer therapies. Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines.</p> <p>Results</p> <p>As a first step towards understanding how Grb7 may be inhibited by G7-18NATE, we solved the crystal structure of the Grb7 SH2 domain to 2.1 Å resolution. We describe the details of the peptide binding site underlying target specificity, as well as the dimer interface of Grb 7 SH2. Dimer formation of Grb7 was determined to be in the μM range using analytical ultracentrifugation for both full-length Grb7 and the SH2 domain alone, suggesting the SH2 domain forms the basis of a physiological dimer. ITC measurements of the interaction of the G7-18NATE peptide with the Grb7 SH2 domain revealed that it binds with a binding affinity of K_d= ~35.7 μM and NMR spectroscopy titration experiments revealed that peptide binding causes perturbations to both the ligand binding surface of the Grb7 SH2 domain as well as to the dimer interface, suggesting that dimerisation of Grb7 is impacted on by peptide binding.</p> <p>Conclusion</p> <p>Together the data allow us to propose a model of the Grb7 SH2 domain/G7-18NATE interaction and to rationalize the basis for the observed binding specificity and affinity. We propose that the current study will assist with the development of second generation Grb7 SH2 domain inhibitors, potentially leading to novel inhibitors of cancer cell migration and invasion.</p

High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A pi-stacking interactions for small-molecule recognition

Aberrant KRAS signaling is a driver of many cancers and yet remains an elusive target for drug therapy. The nuclease hypersensitive element of the KRAS promoter has been reported to form secondary DNA structures called G-quadruplexes (G4s) which may play important roles in regulating KRAS expression, and has spurred interest in structural elucidation studies of the KRAS G-quadruplexes. Here, we report the first high-resolution crystal structure (1.6 A) of a KRAS G-quadruplex as a 5'-head-to-head dimer with extensive poly-A π-stacking interactions observed across the dimer. Molecular dynamics simulations confirmed that the poly-A π-stacking interactions are also maintained in the G4 monomers. Docking and molecular dynamics simulations with two G4 ligands that display high stabilization of the KRAS G4 indicated the poly-A loop was a binding site for these ligands in addition to the 5'-G-tetrad. Given sequence and structural variability in the loop regions provide the opportunity for small-molecule targeting of specific G4s, we envisage this high-resolution crystal structure for the KRAS G-quadruplex will aid in the rational design of ligands to selectively target KRAS.National Health and Medical Research Council; Australian Research Council; National Breast Cancer Foundation; A.O. would like to thank the Australian Government and UWA for scholarships and financial support. Funding for open access charge: University of Western Australia

A substrate mimic allows high-throughput assay of the FabA protein and consequently the identification of a novel inhibitor of <i>Pseudomonas aeruginosa</i> FabA

The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 223461, Senior Investigator Award WT100209MA (JHN), Swedish Science Council (GS), Wellcome Trust Strategic grant 100476/Z/12/Z (DWG) and National Institutes of Health R01GM095970 (MB). JHN & ADS are Royal Society Wolfson Merit Award holders.Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathway(s) that comprise iterative chain elongation, reduction, and dehydration reactions. The bacterial FASII pathway differs significantly from human FAS pathways and is a long-standing target for antibiotic development against Gram-negative bacteria due to differences from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes. N-acetylcysteamine (NAC) fatty acid thioesters have been used as mimics of the natural acyl carrier protein (ACP) pathway intermediates to assay FASII enzymes, and we now report an assay of FabV from Pseudomonas aeruginosa using (E)-2-decenoyl-NAC. In addition, we have converted an existing UV absorbance assay for FabA, the bifunctional dehydration/epimerization enzyme and key target in the FAS II pathway, into a high throughput enzyme coupled fluorescence assay that has been employed to screen a library of diverse small molecules. With this approach, N-(4-chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine (N42FTA) was found to competitively inhibit (pIC50 = 5.7 ± 0.2) the processing of 3-hydroxydecanoyl-NAC by P. aeruginosa FabA. N42FTA was shown to be potent in blocking crosslinking of E. coli ACP and FabA, a direct mimic of the biological process. The co-complex structure of N42FTA with P. aeruginosa FabA protein rationalizes affinity and suggests future design opportunities. Employing NAC fatty acid mimics to developing further high throughput assays for individual enzymes in the FASII pathway should aid in the discovery of new antimicrobials.Publisher PDFPeer reviewe

Bemestingsproef met stikstof en met kali : resultaten van de derde teelt chrysanten (1973)

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>ture elements present in the Grb7 SH2 structure as determined by WHATIF [71] are shaded from purple at the N-terminus to red at the C-terminus. Secondary structure elements of the canonical SH2 domain as defined by Eck . [41] are shown in green and orange symbols above the sequences. The boundaries of these elements differ slightly from that observed in the Grb7 SH2 domain. Residue number is for the Grb7 SH2 domain (b) Cartoon representation of the Grb7 SH2 domain shaded from purple at the N-terminus to red at the C-terminus. The extended DE loop distinguishes this family of SH2 domains from others. (c) A structural comparison of the Grb7 SH2 domain (green) with the Grb7 SH2 domain bound to an ErbB2 derived phosphopeptide (1MW4; black; [29]). The location of the bound phosphopeptide is indicated

Enzymes that catalyse S(N)2 reaction mechanisms

Enzymes have evolved to catalyse reactions, reducing the activation barrier by lowering transition state energy. Many reaction types are represented in enzymology; however, it is noticeable that S(N)2-type nucleophilic reactions at carbon are not common. The activation barrier of an S(N)2 reaction is generally high, as it progresses through a trigonal bipyramidal transition state, and this presents a challenge to efficient catalysis. This review summarises those enzyme reactions which almost certainly take place by a S(N)2 reaction mechanism, although it is recognised that the S(N)2 terminology, which derives from the bimolecular kinetics of a reaction in solution, is compromised to some extent in enzymes as they all display Michealis-Menten kinetics. Nonetheless, the S(N)2 terminology is used here to classify enzymes which catalyse nucleophilic reactions at sp(3)-hybridised carbon. There is a particular focus on highlighting the active-site residues involved in catalysis where known, information that comes primarily from a combination of structural and mutagenesis studies. Predictably, methyl transfer reactions are most widely represented; however, there are a number of enzymes that halogenate/dehalogenate, as well as epoxide hydrolases and inverting sulfatases. Although most of the enzymes have been known for some time, recent advances in structural biology are providing more details on how such enzymes function.</p

Enzymes that catalyse S(N)2 reaction mechanisms

Enzymes have evolved to catalyse reactions, reducing the activation barrier by lowering transition state energy. Many reaction types are represented in enzymology; however, it is noticeable that S(N)2-type nucleophilic reactions at carbon are not common. The activation barrier of an S(N)2 reaction is generally high, as it progresses through a trigonal bipyramidal transition state, and this presents a challenge to efficient catalysis. This review summarises those enzyme reactions which almost certainly take place by a S(N)2 reaction mechanism, although it is recognised that the S(N)2 terminology, which derives from the bimolecular kinetics of a reaction in solution, is compromised to some extent in enzymes as they all display Michealis-Menten kinetics. Nonetheless, the S(N)2 terminology is used here to classify enzymes which catalyse nucleophilic reactions at sp(3)-hybridised carbon. There is a particular focus on highlighting the active-site residues involved in catalysis where known, information that comes primarily from a combination of structural and mutagenesis studies. Predictably, methyl transfer reactions are most widely represented; however, there are a number of enzymes that halogenate/dehalogenate, as well as epoxide hydrolases and inverting sulfatases. Although most of the enzymes have been known for some time, recent advances in structural biology are providing more details on how such enzymes function.</p